ArticleLeukemia2014
WTAP is a novel oncogenic protein in acute myeloid leukemia.
Erratum issuedAbstract readLetter
In one paragraph
Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 171 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
171citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
171 citing papers in PubMed, 2 syntheses or guidelines pooled it, 245 citations in OpenAlex.
- Emerging Roles of mFrontiers in oncology · 2022Pooled it
- Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of Digestive System Tumours.Frontiers in pharmacology · 2022Pooled it
- RNA modifications as determinants of cancer cell death: from epitranscriptomic mechanisms to therapeutic targeting.Functional & integrative genomics · 2026Review
- WTAP mediated mScience China. Life sciences · 2026Article
- mFrontiers in cell and developmental biology · 2026Review
- Structure-based design of anticancer drugs based on β-elemene: Research foundations and development potential.Journal of pharmaceutical analysis · 2025Review
- Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications.Molecular cancer · 2025Review
- RNA epigenetic modifications as dynamic biomarkers in cancer: from mechanisms to clinical translation.Biomarker research · 2025Review
- Hsa_circ_0101308 adjusted by N6-methyladenosine (mCancer biomarkers : section A of Disease markers · 2025Article
- Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias.Science translational medicine · 2025Article
- METTL3, an Independent Adverse Prognostic Factor for AML, Promotes the Development of AML by Modulating the PGC-1α-MAPK Pathway and PGC-1α-Antioxidant System Axis.Cancer medicine · 2025Article
- Epigenetic regulation in oogenesis and fetal development: insights into m6A modifications.Frontiers in immunology · 2025Review
- NAT10-mediated mRNA NNature cell biology · 2024Article
- Characterization of ACTN4 as a novel antiviral target against SARS-CoV-2.Signal transduction and targeted therapy · 2024Article
- N6-methyladenosine RNA modifications: a potential therapeutic target for AML.Annals of hematology · 2024Review
- Research Progress on the Role of M6A in Regulating Economic Traits in Livestock.International journal of molecular sciences · 2024Review
- WTAP promotes proliferation of esophageal squamous cell carcinoma via mCancer science · 2024Article
- Liquid-liquid phase separation in diseases.MedComm · 2024Review
- Identification of 6-methyladenosine sites using novel feature encoding methods and ensemble models.Scientific reports · 2024Article
- The role of RNA-modifying proteins in renal cell carcinoma.Cell death & disease · 2024Review
111 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedProia, D [Corrected to Proia, D A]
Authors and funding
16 authors at 5 institutions in 1 country.
H BansalGreehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, TX, USA.
Q YihuaDepartment of Leukemia & Department of Stem Cell Transplantation and Cellular Therapy, The MD Anderson Cancer Center, Houston, TX, USA.
S P IyerMethodist Cancer Center, Houston, TX, USA.
S GanapathyGreehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, TX, USA.
D A Proia
D ProiaSynta Pharmaceuticals Corp, Lexington, MA, USA.
L O Penalva1] Greehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, TX, USA [2] Department of Cellular and Structural Biology, The University of Texas Health Science Center, San Antonio, TX, USA.
P J UrenDivision of Biological Sciences at University of Southern California, Los Angeles, CA, USA.
U SureshGreehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, TX, USA.
J S CarewInstitute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, TX, USA.
A B KarnadDepartment of Medicine, The University of Texas Health Science Center, San Antonio, TX, USA.
S WeitmanInstitute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, TX, USA.
G E TomlinsonGreehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, TX, USA.
M K Rao1] Greehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, TX, USA [2] Department of Cellular and Structural Biology, The University of Texas Health Science Center, San Antonio, TX, USA.
S M KornblauDepartment of Leukemia & Department of Stem Cell Transplantation and Cellular Therapy, The MD Anderson Cancer Center, Houston, TX, USA.
S BansalGreehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, TX, USA.
The University of Texas Health Science Center at San Antonio · USThe University of Texas Health Science Center · USThe University of Texas MD Anderson Cancer Center · USSynta Pharmaceuticals (United States) · USUniversity of Southern California · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1MCatenins: A role in spertmatogenesis and sperm maturationR01HD057118 · NICHD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI RAO, MANJEET KUMAR · 2009 to 2010
$594kNCI NIH HHS CA054174NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA054174NICHD NIH HHS HD057118NICHD NIH HHS R01 HD057118
Abstract
PubMed holds no abstract for this paper.
Indexed as
Cell Cycle ProteinsHumansLeukemia, Myeloid, AcuteNuclear ProteinsRNA Splicing FactorsCell Cycle ProteinsNuclear ProteinsRNA Splicing FactorsWTAP protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.